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Abstract
The ongoing COVID-19 pandemic is likely to have a pro-
found impact on the lives of high-risk drug users and on the 
services responding to their needs in at least two important 
ways: first, through the restrictive measures introduced to 
mitigate the spread of the virus and, second, as a result of 
extensive economic downturn. Currently there is great un-
certainty as to the future intensity and duration of the pan-
demic. In addition, the lessons we have been able to learn 
from previous economic downturns may be of limited appli-
cability to the current situation, which differs in a number of 
significant respects. Experience nevertheless suggests that 
the potential consequences for drug users’ health and well-
being may be severe. The ongoing uncertainty serves to un-
derline the importance of close monitoring of the drug situ-
ation and preparing flexible and innovative solutions to be 
able to meet new challenges which may arise.
© 2021 S. Karger AG, Basel
Introduction
COVID-19 containment measures have had a direct 
and documented impact on drug use and service respons-
es [1–3]. In a European context, at the start of the pan-
demic, localized shortages of heroin were reported in 
some countries resulting in the use of replacement sub-
stances [3]; more generally, increases in consumption of 
alcohol and prescription medicines are noted, especially 
benzodiazepines [2]. There is evidence to suggest that in 
the first weeks of lockdown, some people with frequent or 
intensive patterns of drug use increased their consump-
tion, while increased emergency presentations for mental 
health problems have been documented [2]. A decline in 
the availability of drug services and reduction in users 
seeking treatment were also observed in the early months 
of the pandemic. After the initial phase, however, there 
are many examples of services manifesting rapid, adap-
tive, and innovative responses to extraordinarily chal-
lenging circumstances [2].
In addition, the numerous mitigation and confine-
ment measures implemented by governments in response 
to the pandemic are having marked and potentially long-
lasting impacts on societies and economies. Gross Do-
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mestic Product (GDP) is falling abruptly in many coun-
tries; governments are increasing their levels of indebt- 
edness; temporary unemployment schemes are being 
widely implemented, and unemployment is rising. It is 
not so long, however, since the global economy last expe-
rienced an economic shock, and the impact of the 2008 
recession on drug problems is still fresh in the minds of 
many. Studies suggest that the 2008 global recession was 
associated with a broad range of consequences for high-
risk drug users (HRDU), including reports from some 
countries of the increases in use of heroin [4–6], increas-
es in opioid users requiring clinical treatment, increased 
levels of drug injecting and HIV cases among people who 
inject drugs, higher HIV-related mortality [7, 8], decreas-
ing median age of injecting drug users [9], and an in-
creased risk of “deaths of despair” [10, 11]. The question 
many may now be asking is whether the developing eco-
nomic crisis will result in similar consequences for drug-
related harms and service provision this time around. Be-
fore answering, we wish to highlight some essential dif-
ferences that will likely impact on the outcome.
How Does the COVID-19 Recession Differ from the 
2008 Recession?
First, the intensity of the “COVID-19 recession” ap-
pears to be significantly greater. Preliminary estimates in-
dicate that GDP in many countries may drop by 10% or 
more in 2020. This is approximately double the decline 
observed during the 2008 recession. Second, there is still 
uncertainty about its duration. It depends on how the 
coronavirus behaves as well as the effectiveness of our re-
sponses to it (a mutation of the virus? new outbreaks? 
availability of a vaccine?). Third, the “fear factor” differs 
from the past. Now, it is not only related to socioeconom-
ic issues but also linked to the overall health status of pop-
ulations. “Fear” impacts on the behaviour of individuals 
and nations, making a strong recovery more difficult. 
Fourth, the extensive economic implications of CO-
VID-19 have forced governments to substantially in-
crease spending on recovery plans in order to stop the 
downward deflationary spiral. This may lead to budget 
deficits that greatly exceed those of the previous reces-
sion. In particular, weaker economies could be forced to 
impose austerity measures to cover the spending on re-
covery programmes, precisely at a time when the econo-
my should be stimulated. Finally, income inequality with-
in and between countries is more pronounced now than 
in 2008. The confinement measures, hitting socioeco-
nomic groups unequally, may widen this gap even fur-
ther. In sum, the consequences of the current recession 
are likely to surpass previous experiences.
What Are the Potential Consequences for High-Risk 
Drug Users and Services?
Negative effects of the confinement measures are like-
ly to exacerbate existing socioeconomic problems. And 
while the impact of the confinement measures is likely to 
be more immediate, the effects of the COVID-19 reces-
sion will undoubtedly endure over a longer time period 
and continue to negatively impact on the lives of HRDU. 
Rising unemployment and economic hardship have the 
clear potential to increase levels of poverty, marginaliza-
tion, and social exclusion. In practical terms, reduced per-
sonal income will mean less money for food, housing and 
health care. Poor and diminished health status in turn 
potentially impact on an already exaggerated mortality 
rates (up to 15 times higher for injecting drug users than 
for the general population) [12].
In some countries, COVID-19 mitigation measures 
have already resulted in the closure and reduction of drug 
treatment and harm reduction services, and it appears in-
evitable that tougher budget constraints will jeopardize 
future investment in and potentially the long-term sur-
vival of some interventions. Consequently, any failure to 
protect essential drug services from this double blow of 
mitigation plus recession measures may have severe re-
percussions for the health and well-being of HRDU pop-
ulations. Nevertheless, while continuing to assessing risks 
and evaluate possible unintended consequences, it will be 
important to support best practices emerging as a re-
sponse to these challenges. Many examples have been 
documented including expanded take-home schemes for 
opioid substitution medicines; increased use of long-act-
ing depot buprenorphine; extended prescription periods; 
and the home delivery of medicines and clean injection 
equipment. Across the board, health services, including 
drug services, have demonstrated flexible use of digital 
health care/telemedicine for improving access and avail-
ability of essential services throughout the pandemic.
Conclusion
Following the 2008 recession, drug-related spending 
either stagnated or declined in many countries [13]. In 
2020, we suggest that a safeguarding of drug-related bud-
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gets is required, especially for financing proven cost-ef-
fective interventions [14]. Already in 2014, the Commis-
sion on Narcotic Drugs of the United Nations encour-
aged countries to ensure that responses to economic 
downturns do not disproportionately affect people suf-
fering from drug-related problems and diseases [15]. 
Now is the time to act upon the request.
The economic consequences are likely to dramatically 
amplify the effects of COVID-19 mitigation measures on 
the lives of HRDU, on their consumption patterns and on 
the survival chances of responding services. The situation 
needs to be closely monitored and flexible and innovative 
solutions prepared. It will be crucial to protect core drug-
related health services, in addition to harm reduction and 
prevention measures [2].
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